| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.ayurvedganga.com | |
| Market Cap | 11.37 Cr. | |
| Enterprise Value(EV) | 13.10 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.08 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | 289.13 | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 41.74 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 13.51 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 1.74 | Calculated using Price: 23.50 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.48 Cr. | 4,836,500 Shares |
| FaceValue | 10 | |
| About Ganga Pharmaceuticals Ltd. | ||
| The company is a producer of quality bulk ayurvedic medicines in Mumbai. Apart from manufacturing, the company is also into marketing, distribution of Bulk Ayurvedic Medicines. Its product includes Ampachan Vati; Khadira Vati; Nirmalaya churna etc. Its products are available in liquid dosage form and solid dosage forms. | ||
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
-3.73% |
| 3 Month |
|
-13.28% |
| 6 Month |
|
+97.81% |
| 1 Year |
|
+68.70% |
| 2 Year |
|
+129.27% |
| 5 Year |
|
+291.67% |
| 10 Year |
|
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 1.28 | 1.36 | 1.57 | 1.91 | 3.7 | 3.59 | 0.38 | 0.7 | 0.72 | |
| Return on Capital Employed (%) | 8.03 | 6.88 | 6.15 | 5.83 | 7.26 | 7.18 | 3.36 | 3.41 | 3.38 | |
| Return on Assets (%) | 0.64 | 0.77 | 0.99 | 1.19 | 2.34 | 2.46 | 0.27 | 0.48 | 0.49 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 3 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | |
| Non Curr. Liab. | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Curr. Liab. | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 5 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | |
| Non Curr. Assets | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | |
| Curr. Assets | 2 | 5 | 4 | 5 | 4 | 4 | 5 | 5 | 5 | 6 | |
| Misc. Exp. not W/O | 0 | ||||||||||
| Total Assets | 5 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | |
| Total Expenditure | -2 | -2 | -2 | -3 | -3 | -3 | -3 | -2 | -2 | -3 | |
| PBIDT | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash Fr. Inv. | 0 | 0 | -1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash Fr. Finan. | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Thu, 25 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Priti Kothari Bhaiya Designation: Company Secretary and Compliance Officer EmailId: ayurvedganga@gmail.com Name of the Chief Financial Officer: Anagh B Sharma Designation: Chief Financial Officer EmailId: gangapharmaltd@gmail.com Date: 25/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Thu, 11 Apr 2024
Submission Of Certificate Under Clause 40(10) Of SEBI (LODR) Regulation 2015 For The Year Ended On March 31 2024 Submission of Certificate under clause 40(10) of SEBI (LODR) Regulation 2015 for the year ended on March 31 2024 |
|||||||||||||||||||||
|
Sat, 06 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Reg. 74(5) of the SEBI (DP) Regulation 2018 for the quarter ended on March 31 2024 |
|
No Scans Found |
